The Future of Indirect Evidence.
Familiar statistical tests and estimates are obtained by the direct observation of cases of interest: a clinical trial of a new drug, for instance, will compare the drug's effects on a relevant set of patients and controls. Sometimes, though, indirect evidence may be temptingly available, perhaps the results of previous trials on closely related drugs. Very roughly speaking, the difference between direct and indirect statistical evidence marks the boundary between frequentist and Bayesian thinking. Twentieth-century statistical practice focused heavily on direct evidence, on the grounds of superior objectivity. Now, however, new scientific devices such as microarrays routinely produce enormous data sets involving thousands of related situations, where indirect evidence seems too important to ignore. Empirical Bayes methodology offers an attractive direct/indirect compromise. There is already some evidence of a shift toward a less rigid standard of statistical objectivity that allows better use of indirect evidence. This article is basically the text of a recent talk featuring some examples from current practice, with a little bit of futuristic speculation.
Department of Statistics, Stanford University, Stanford, California 94305.
Bradley
B
Efron
Cancer Cell. 2002 Mar;1(2):203-9
12086878
J Am Stat Assoc. 2009 Sep 1;104(487):1015-1028
20333278
Magn Reson Med. 2005 Jun;53(6):1423-31
15906307
Nephrol Dial Transplant. 2008 Jan;23(1):213-22
17890749
Science. 1999 Oct 15;286(5439):531-7
10521349